Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Procalcitonin as a Marker of Bacterial Pneumonia
This study has been completed.
Sponsored by: Skejby Hospital
Information provided by: Skejby Hospital
ClinicalTrials.gov Identifier: NCT00415753
  Purpose

Objective: To evaluate PCT as a marker of bacterial community acquired pneumonia in a Danish Hospital setting. To test if it is possible to reduce the use of antibiotics and the length of stay in hospital, and the willingness of the clinicians to take this new marker under advisement in their choice of treatment.

The study is a randomised, controlled intervention study. All adult patients admitted to the Department of Infectious Disease at Skejby hospital suspected of a lower respiratory tract infection (e.g. CAP, acute exacerbation of COPD and bronchitis) are eligible for inclusion. Patients are randomised to have either PCT guided treatment or standard care, in which case the doctor will not learn the PCT test result. In the PCT group the antibiotic treatment will be based on serum PCT as follows: If PCT is less than 0.25 µg/L antibiotic treatment is discouraged; if PCT is greater than 0.25 µg/L antibiotic treatment is encouraged and if PCT is greater than 0.5 µg/L antibiotic treatment is strongly encouraged. The treating doctor is allowed to overrule the treatment guidelines. The control group will receive antibiotics according to usual practice.

The primary endpoints are antibiotic use and length of stay in hospital. Secondary endpoint is the proportion of patients where the treating doctor chooses to disregard the guidelines.


Condition Intervention
Pneumonia
Bronchitis
COPD
Behavioral: No antibiotics if se-procalcitonin is below stated limit

MedlinePlus related topics: Antibiotics Bronchitis Pneumonia
Drug Information available for: Procalcitonin
U.S. FDA Resources
Study Type: Interventional
Study Design: Diagnostic, Randomized, Open Label, Dose Comparison, Factorial Assignment, Efficacy Study

Further study details as provided by Skejby Hospital:

Primary Outcome Measures:
  • Antibiotic use
  • Length of stay in hospital

Secondary Outcome Measures:
  • The proportion of patients where the doctor chooses to disregard treatment guidelines

Enrollment: 223
Study Start Date: June 2006
Study Completion Date: August 2007
Primary Completion Date: April 2007 (Final data collection date for primary outcome measure)
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • suspected lower respiratory tract infection
  • must be able to give consent

Exclusion Criteria:

  • age under 18 years
  • not able to give consent
  • admitted not primarily because of the respiratory tract infection
  • hospital acquired infections
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00415753

Locations
Denmark
Department of Infectious Diseases, Skejby Hospital
Aarhus N, Denmark, 8200
Departement of Medicin, Silkeborg Hospital
Silkeborg, Denmark, 8600
Sponsors and Collaborators
Skejby Hospital
Investigators
Study Chair: Finn T Black, Professor Aarhus Universityhospital
Principal Investigator: Kristina B Kristoffersen Skejby Hospital
  More Information

Publications:
Responsible Party: Skejby Hospital
Study ID Numbers: 271-05-0765
Study First Received: December 22, 2006
Last Updated: May 22, 2008
ClinicalTrials.gov Identifier: NCT00415753  
Health Authority: Denmark: Danish Dataprotection Agency;   Denmark: The Regional Committee on Biomedical Research Ethics

Study placed in the following topic categories:
Lung Diseases, Obstructive
Respiratory Tract Infections
Respiratory Tract Diseases
Lung Diseases
Pneumonia, Bacterial
Bronchitis
Pneumonia

Additional relevant MeSH terms:
Bronchial Diseases

ClinicalTrials.gov processed this record on January 16, 2009